About the Study
Baptist Health Center for Clinical Research has been selected as one of the first two sites in the U.S. to study a novel COVID prevention agent, using two monoclonal antibodies instead of a vaccine. This new study could begin in the next few days.
Participants must be over 18 and there is no upper limit to participate. This is not a vaccine. Instead, the antibodies bind to the COVID-19 spike protein and prevent COVID from replicating and thereby prevent disease. Of the participants, 67 percent will get the antibody in the form of a shot, and 33 percent of participants will receive the placebo.
AstraZeneca’s long-acting antibody combination will advance into Phase III clinical trials with approximately 5,000 participants in and outside the U.S. These antibodies have been engineered so that they last longer in the body, as long as six to 12 months following a single administration.
The trial will evaluate the safety and efficacy of these antibodies to prevent infection for up to 12 months.
If you are interested and would like more information, please fill out the contact form on this page. Filling out the form does not commit you to the study, but you will be contacted to provide more information and to answer additional questions.
Study-related care is available to participants at no cost and health insurance is not required, nor needed. Participants will be compensated, up to $875 for time and travel, if they qualify and enroll in the study.
Thanks again for all you are doing as we fight this pandemic together!
- 18+ years old
- Please note, other conditions may apply.